EMA Authorised: Nemdatine (memantine) — Actavis Group PTC ehf

View source ↗

Summary

EMA authorised Nemdatine (memantine) for Alzheimer disease; marketed by Actavis Group PTC ehf. Decision date 16/01/2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Nemdatine (memantine)

Snippet

Status: Authorised. Therapeutic area: Alzheimer Disease. MAH: Actavis Group PTC ehf. Decision date: 16/01/2024